| Literature DB >> 32230934 |
Sivakumar Allur Subramaniyan1, Darae Kang1, Sharif Hasan Siddiqui1, Jinryong Park1, Weishun Tian2, Byungyong Park2, Kwanseob Shim1.
Abstract
The aim of the study was to analyze the in ovo injection of inorganic and organic synthesizedEntities:
Keywords: L-arginine; conjugation; muscle growth; nanoparticles; silver
Year: 2020 PMID: 32230934 PMCID: PMC7222345 DOI: 10.3390/ani10040564
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Experimental design for dose (L-Arg and conjugate with Brassica oleracea L. var. capitate F. rubra (BOL)-Ag NPs and C-Ag NPs) with different embryonic stage (8th day, 14th day and 18th day).
| Group | Dosage | No. of Replication | Total No. of Eggs |
|---|---|---|---|
| 1C | Control | 4 | 80 |
| 1C1 (8th day) | PBS/100 µL/egg | 4 | 80 |
| 1Tb (8th day) | 100 µg (L-Arg) + 1000 µg (BOL-Ag NPs)/100 µL/egg | 4 | 80 |
| 1Tc (8th day) | 100 µg (L-Arg) + 100 µg (C-Ag NPs)/100 µL/egg | 4 | 80 |
| 2C1 (14th day) | PBS/100 µL/egg | 4 | 80 |
| 2Tb (14th day) | 100 µg (L-Arg) + 1000 µg (BOL-Ag NPs)/100 µL/egg | 4 | 80 |
| 2Tc (14th day) | 100 µg (L-Arg) + 100 µg (C-Ag NPs)/100 µL/egg | 4 | 80 |
| 3C1 (18th day) | PBS/100 µL/egg | 4 | 80 |
| 3Tb (18th day) | 100 µg (L-Arg) + 1000 µg (BOL-Ag NPs)/100 µL/egg | 4 | 80 |
| 3Tc (18th day) | 100 µg (L-Arg) + 100 µg (C-Ag NPs)/100 µL/egg | 4 | 80 |
In ovo Injection and Treatment Groups.
Figure 1TEM images of Ag NPs (BOL-Ag NPs and C-Ag NPs), L-Arg and bio-complex of L-Arg with BOL-Ag NPs and L-Arg with C-Ag NPs.
Figure 2(A–D) Nature of functional groups and structure of the BOL extract and Ag NPs and conjugation of L-Arg with BOL-Ag NPs assessed by FT-IR spectra.
Figure 3(A) Energy-dispersive X-ray spectroscopy profile of L-arginine; (B) biosynthesized (BOL) Ag NPs; (C) CHE-Ag NPs; (D) Conjugation of L-Arg with BOL-Ag NPs.
Figure 4Effects of in ovo injections of L-Arg (100 μg) with 1000 µg (BOL-Ag NPs) or L-Arg (100 μg) with 100 µg (C-Ag NPs) at different developmental embryonic stages on survival rate. Small characters indicate significant differences among experimental groups at p < 0.05. Values are presented as mean ± SD from (n = 12) determinations.
Figure 5Effects of in ovo injections of L-Arg (100 μg) with 1000 µg (BOL-Ag NPs) or L-Arg (100 μg) with 100 µg (C-Ag NPs) at different developmental embryonic stages on hatching rate. Small characters indicate significant differences among experimental groups at p < 0.05. Values are presented as mean ± SD from (n = 12) determinations.
Figure 6Effects of in ovo injections L-Arg (100 μg) with 1000 µg (BOL-Ag NPs) or L-Arg (100 μg) with 100 µg (C-Ag NPs) at different developmental embryonic stages on chick weight. Small characters indicate significant differences among experimental groups at p < 0.05. Values are presented as mean ± SD from (n = 12) determinations.
Figure 7Effects of in ovo injections of L-Arg (100 μg) with 1000 µg (BOL-Ag NPs) or L-Arg (100 μg) with 100 µg (C-Ag NPs) at different developmental embryonic stages on serum glutamate oxaloacetate transaminase (SGOT) (A) and serum glutamate pyruvate transaminase (SGPT) (B) concentrations in serum. Small characters indicate significant differences among experimental groups at p < 0.05.
Figure 8L-Arg induces IgM levels in different stages of chicken embryos. Small characters indicate significant differences among experimental groups at p < 0.05. Values are presented as mean ± SD from (n = 12) determinations.
Figure 9(i) Expression levels of L-Arg, HSP-60 and HSP-70 as well Myogenin and MyoD protein expression levels in different stages of chicken embryos after injection at different doses. Small characters indicate significant differences among experimental groups at p < 0.05. Figure 9 (ii) (A–D) bar graph represents quantitative expression of different proteins in all groups. Data are expressed as the ratio of relative intensity to the level of β-actin.